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Abstract
Background The PERFORM Questionnaire is a 12-item
scale developed for assessing fatigue in cancer patients in
the clinical practice. It has advantages over other tools in
that it is short and includes beliefs and attitudes of patients
about fatigue. It was psychometrically validated in cancer
patients with and without anemia.
Purpose We evaluated the usefulness of the PERFORM
scale to measure fatigue in a large study focusing exclusive-
ly on anemic patients.
Methods This was an observational, multicenter, prospec-
tive, 3-month study in cancer patients with hemoglobin
(Hb)≤11 g/dl. Fatigue was assessed using the PERFORM
questionnaire. The overall score ranges from 12 (no fatigue)
to 60 (maximum fatigue).
Results We included 667 patients: 54.1 % women, mean age
60 (standard deviation, 12)years. A highly significant, but mild
correlation was observed between low baseline Hb and high
patient perception of fatigue (r with PERFORM score=−0.215,
p<0.0001). Of the patients, 65.8 % improved Hb level during
follow-up (increase of ≥1 g/dL and/or achieving >11 g/dL),
which translated into a significant improvement in the PER-
FORM score [mean (95 % confidence interval (CI)] change,
−1.2 (−0.04 to −2.4), whereas more fatigue was observed in
patients without improvement in Hb [change (95 % CI) in
PERFORM, +3.3 (1.5 to 5)]. In a multivariate linear regression
analysis, the independent factors associated to fatigue at
3 months were a low Hb level, a low Karnofsky index, active
chemotherapy, cancer treatment with palliative intention, and
transfusion need in the last 3 months.
Conclusions Minimal increases or decreases in Hb of ≥1 g/dL
were associated with meaningful changes in patient-perceived
fatigue as measured with the PERFORM questionnaire. In
addition to anemia severity, other factors such as active che-
motherapy and advanced disease contribute to perception of
fatigue by cancer patients.
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Introduction
Fatigue is one of the cancer symptoms with greatest impact in
the patients’ daily lives, and it is gaining importance as out-
comemeasure [1]. In a recent survey, it was found that 80% of
patients experienced fatigue at least 50 % of the time during
treatment, and fatigue was ranked as the symptom most
impacting daily life, independently of gender or tumor type
[2]. The underlying pathophysiology of cancer-related fatigue
is very complex and not completely understood [3]. Although
some common mechanisms seem to participate, it is probable
that the etiology is not the same in all cancer subpopulations
(i.e., patients undergoing active chemotherapy, patients with
advanced age, survivors or those with palliative care). It is
very important to correctly identify both the biological and
psychosocial determinants of fatigue, in order to individualise
the therapeutic management.
The etiology of cancer-related fatigue is multifactorial and is
related to a variety of factors including chemotherapy with
alkylating agents, antimetabolites or platinum compounds, ra-
diotherapy or bone marrow transplantation, changes in blood
volume, excess lactate production, hypoglycemia, hypotension,
generalized stress responses with or without endocrine dysfunc-
tion, sleep disturbances, anxiety, or depression [4–9]. Anemia is
one of the factors identified as a causative element in the fatigue
experience [10]. Several studies have demonstrated an associa-
tion between the hemoglobin (Hb) level or its change over time
and fatigue intensity assessed by means of Linear Analogue
Self-Assessment (LASA) and visual analogue scale (VAS)
[11–13]. Furthermore, an association between low hemoglobin
and impaired quality of life has also been observed [14].
Anemia is a common complication in cancer patients.
According to the European Cancer Anaemia Survey (ECAS),
it is present in 72 % of non-solid and 62 % of solid tumor
patients [15]. The underlying causes of low Hb levels include
chemotherapy with platinum salts, which affect erythropoietin
(EPO) production secondarily to nephrotoxicity [16], direct
bone marrow damage, caused by almost all cytotoxic drugs
[17–19], or also the underlying malignancy itself, which direct-
ly decreases erythropoiesis due to an attenuated endogenous
EPO response. Chronic anemia of cancer is also characterized
by generalized hypoxia, which results in severe fatigue [20].
Other proposed mechanisms of cancer-related fatigue are a
dysregulation of the immune function, a dysfunction of the
hypothalamic–pituitary–adrenal axis, altered central nervous
system serotonin neurotransmitter activity, vagal afferent sig-
naling, and alterations in muscle metabolism [3]. Several
findings support these hypotheses. For example, elevat-
ed levels of inflammatory cytokines [21], circulating T
lymphocytes [22], increased neutrophil counts [23], and
blunted cortisol responses [24, 25] have been found to be
associated to fatigue in cancer patients. Other studies have
identified associations with sleep disturbances [26–28].
The PERFORM questionnaire is a brief, 12-items scale
which was developed under the auspice of the Spanish Society
of Medical Oncology. In the validation study performed in
437 patients with and without anemia, it demonstrated good
psychometric properties (overall Cronbach’s alpha and
intraclass correlation coefficient of 0.94 and 0.83, respective-
ly; effect size of 0.57 for improved patients and −1 for wors-
ened patients; minimally important difference of 3.5) and
accurately reflected improvements in Hb levels [29]. Thus,
the PERFORM questionnaire constitutes a good tool to assess
perceptions of fatigue of cancer patients in the clinical prac-
tice. In order to continue our observations, we have performed
a large study focusing exclusively on anemic patients.
The main objective was to prospectively evaluate the asso-
ciation between the Hb level (and its change over time) and
self-perceived fatigue and quality of life in cancer patients
with anemia, controlling by possible confounding factors
(age, gender, tumor type and stage, cancer treatments, pres-
ence of comorbidities such as anxiety, depression, malnutri-
tion, sleep disorders, etc.). All these factors were collected,
and its effect on fatigue was evaluated simultaneously with the
effect of Hb level by means of a multivariate analysis, which
allowed the estimation of the independent effects. The sec-
ondary objectives were to describe anemia management in the
clinical practice of Spanish oncology services and to search
other clinical, biochemistry, or sociodemographic factors as-
sociated to cancer-related fatigue.
Patients and methods
Study design and population
We performed a prospective, multicenter, observational, 3-
month study between September 2007 and July 2008 in
medical oncology or palliative care departments of 60
Spanish hospitals. The inclusion criteria were: ambulatory
patients ≥18 years of age; with a diagnosis of cancer
(any site and length of disease duration); with life ex-
pectancy of at least 6 months; and with anemia (symp-
tomatic or asymptomatic) defined as Hb ≤11 g/dl, on
inclusion. All eligible subjects who fulfilled the inclusion
criteria and provided informed consent were consecutively
enrolled in the study. The sample size was calculated based
on having 80 % power to detect as significant, at a probability
of type I error (alpha) of 0.05, a correlation coefficient of at
least 0.1 between longitudinal changes in PERFORM overall
score and Hb levels. The calculated number of patients re-
quired was 660. The study was approved by the Ethics Com-
mittee of the Hospital Clínic in Barcelona and has therefore
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been performed in accordance with the ethical standards laid
down in the Declaration of Helsinki.
Variables and procedures
Sociodemographic and clinical characteristics, and hematol-
ogy (hemoglobin, hematocrit, leucocyte, lymphocytes, neu-
trophils, platelets), biochemistry (sodium, potassium, aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), glucose, albumin, bilirubin, creatinine, lactate-
dehydrogenase (LDH), serum iron, ferritin, transferrin, vita-
min B12, folic acid, endogenous EPO), and fatigue mea-
sures were collected at baseline visit and 3 months later.
Patient perception of fatigue was assessed using the PER-
FORM questionnaire and two additional instruments, in-
cluded as control measures: the LASA scale and a VAS.
The PERFORM Questionnaire (Appendix) is a recently
developed questionnaire for assessing patient perception on
cancer-related fatigue [29, 30]. After the generation of a “pool”
of 75 candidate items [31], they were administered to a sample
of oncology patients in the preliminary assessment study,
conducted between January and September 2005 [30]. The
psychometric properties of the final, 12-item version were
assessed in the validation study, conducted between November
2005 and September 2006, which showed good feasibility,
internal consistency, test–retest reliability, convergent validity,
and sensitivity to change [29]. The 12 items, whose responses
are on a five-point Likert scale, are distributed in three di-
mensions “Physical Limitations,” “Activities of Daily Living,”
and “Beliefs and Attitudes.” An overall score (range from 12
(no fatigue) to 60 (maximum fatigue)) and three dimension
subscores (range from 4 to 20) are obtained, with high scores
indicating worse patient perception of cancer-related fatigue.
The LASA scale, previously used for assessing health-
related quality of life in cancer patients [12, 32], consists of
three items (range for each one from 0 (worse quality of life
(QoL)) to 100 (best QoL)): energy scale, activities of daily
living, and overall QoL. Each of them identifies a relevant
dimension in the evaluation of quality of life in cancer
patients. The LASA scale correlates well with Hb levels
and has shown good reproducibility and sensitivity to
change, with minimally important differences of 9.6 for
energy level, 8.7 for activities of daily living, and 9.8 for
overall QoL [12]. Finally, each patient self-rated fatigue
intensity on a 100-mm horizontal VAS.
Statistical analysis
Correlations between Hb level and patient perception of
fatigue at baseline, and between changes in Hb level and
changes in fatigue scores during the follow-up were evalu-
ated by using Spearman rank correlation tests. Since the
fatigue measures had a normal distribution (confirmed with
the Kolmogorov–Smirnov test), changes along time were
analyzed using paired T tests in the overall sample and in
subgroups of patients defined by an improvement or not in
their Hb level during the study (increase of ≥1 g/ dL or
achieving >11 g/dL). Mean changes and baseline values
between subgroups were compared using Mann–Whitney
tests or Student’s T tests (as applicable). The sensitivity to
change was assessed by calculating the effect size (i.e., the
standardised mean score change) in the subgroups of
patients with and without improvement in Hb levels.
Changes in hematology and serum biochemistry parame-
ters between baseline and 3-month visits were evaluated
using paired T tests.
Bivariate associations between patients’ characteristics
(sociodemographic and clinical variables, hematology and
biochemistry values) and fatigue measures were assessed
using Student’s T tests or analysis of variance. Effect measures
were expressed as difference in means together with the 95 %
confidence interval with respect to the reference category (the
one with less fatigue). A multivariate linear regression model
was built to identify the independent factors associated to
perception of fatigue (overall PERFORM score) at 3 months.
Statistical analyses were performed with the SAS® package
version 8.2. (SAS Institute, Cary, NC, USA).
Results
Demographic and clinical characteristics
The study included 667 cancer patients with anemia. Themain
characteristics of the study population are shown in Table 1.
Hematology and serum biochemistry parameters where
mostly within normal limits (Table 2), both at baseline and
3-month visit, with the exception of: low hematocrit and Hb
levels (as defined by protocol), and elevated mean LDH and
endogenous EPO levels. Ferritin levels were in the upper
limit of normality. During the prospective follow-up, the Hb
(p<0.001), hematocrit (p<0.001), serum iron (p=0.026),
AST (p=0.002), and albumin levels (p<0.001) displayed a
significant increase, whereas the platelet count (p<0.001)
and the glucose levels (p=0.007) decreased (Table 2).
Evolution and management of anemia
At baseline, 65.1, 33.3, and 1.6 % of patients had mild (>10 to
≤11 g/dL), moderate (≥8 to ≤10 g/dL), and severe anemia
(<8 g/dL), respectively (Table 3). At 3 months, the percentage
of anemic patients had decreased to 43.3 %, and 65.8 % of
patients had an improvement in their Hb level (defined as
increase of ≥1 g/dL or achieving >11 g/dL). The severity of
anemia in the subgroup of patients who remained with Hb
<11 g/dL was similar than at baseline (Table 3).
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Only 42.4 % of patients received treatment for anemia at
baseline visit, mainly erythropoiesis-stimulating agents
(ESAs) and/or supplements (87 % iron supplementation;
Table 3). At 3-month visit, the percentage of patients with
treatment for anemia had increased to 55.8 % (p<0.001), but
the relative distribution of the different treatments was sim-
ilar (Table 3).
Patients treated with transfusions alone or in combi-
nation had lower mean baseline Hb level (9.1 (standard
deviation (SD), 1.0)g/dL) than any other group (10.0
(SD, 0.7)g/dL in patients with ESA alone, 9.8 (SD, 0.7)
g/dL in patients with ESA and supplements, 10.2 (SD,
0.7)g/dL in patients with supplements alone, and 10.3
(SD, 0.6)g/dL in patients without treatment, p<0.0001
between groups). Mean change in Hb during the follow-
up was similar in all these subgroups (p=0.511, data
not shown).
Fatigue measures and correlation with Hb
Table 3 displays mean fatigue scores at baseline and 3-month
visits in the overall group for the three administered instru-
ments. At baseline, both the PERFORMquestionnaire and the
two control measures (LASA and VAS) reflected an impair-
ment of medium-degree intensity. Mean PERFORM overall
score at baseline in patients with mild, moderate, and severe
anemia was 31.6 (SD, 12.5), 36.6 (SD, 13.9), and 41.6 (SD,
11.9), respectively.
At 3 months, a significant improvement in fatigue was
observed as measured by the “Beliefs and attitudes” dimen-
sion of the PERFORM questionnaire (p=0.036) and by the
three LASA subcales (p=0.006, 0.003, and 0.004, respec-
tively; Table 3).
Table 1 Demographic and clinical characteristics of the study popu-









Gender, N (%) 667
Men 306 (45.9) –
Women 361 (54.1) –
Age (years) 667
Mean (SD) 59.9 (12.1) –
Range [20–89] –
Cancer typeb, N (%) 667
Breast 129 (19.3) –
Lung 133 (19.9) –
Ovarian 52 (7.8) –
Head and neck 33 (5.0) –
Genitourinary 49 (7.3) –
Gastrointestinal 194 (29.1) –
Lymphoma 16 (2.4) –
Other 117 (17.5) –
Time since diagnosis (years) 657
Mean (SD) 2.1 (3.1) –
Range [0–27.4] –
Family situation, N (%) 665
Patient does not need care from
another person
450 (67.7) –
Patient needs and receives care
from a relative, a caregiver
or both
215 (32.3) –
Spread of cancer, N (%) 666 537
Local 123 (18.5) 113 (21.0)
Locoregional 163 (24.4) 111 (20.7)
Metastatic 380 (57.1) 313 (58.3)
Karnofsky index (%) 651
Mean (SD) 81.8 (12.1) –
Range [1–100] –
Cancer treatment, N (%) 667 541
Without treatment 62 (9.3) 176 (32.5)
In treatmentb 605 (90.7) 365 (67.5)
Chemotherapy 553 (82.9) 220 (40.7)
Monoclonal antibodies 43 (6.4) 35 (6.5)
Radiotherapy 48 (7.2) 23 (4.3)
Hormone therapy 20 (3.0) 28 (5.2)
Interferon 1 (0.1) 1 (0.2)
Symptomatic treatment 70 (10.5) 54 (10.0)
Pain 51 (7.6) 36 (6.7)
Other 28 (4.2) 34 (6.3)
Treatment intention 602 365
Adjuvant 111 (18.4) 57 (15.6)
Curative 83 (13.8) 38 (10.4)
Palliative 408 (67.8) 270 (74.0)
Comorbiditiesb 667










Depression 65 (9.7) 58 (10.7)
Dehydration 4 (0.6) 4 (0.7)
Infection 8 (1.2) 7 (1.3)
Heart failure 10 (1.5) 13 (2.4)
Respiratory failure 42 (6.3) 32 (5.9)
Chronic kidney disease 14 (2.1) 10 (1.8)
Liver disease 14 (2.1) 13 (2.4)
Malnutrition 12 (1.8) 25 (4.6)
Diarrhoea 5 (0.75) 2 (0.4)
Sleep disorders 24 (3.6) 17 (3.1)
SD standard deviation
a There were missing values in the data set
b Each patient could have more than one response
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At baseline, the correlations between fatigue measures and
Hb level were statistically significant in all cases, and showed
relationships of moderate degree (r=−0.215, −0.187, −0.221,
−0.164, p<0.001 in all cases, for the PERFORM overall,
activities of daily living, beliefs and attitudes, and physical
limitations scores; r=−0.134, p<0.001 for the VAS score; and
r=0.108, p=0.005, r=0.099, p=0.01 and r=0.103, p=0.007
for the energy, activities of daily living, and overall QoL
LASA subscales, respectively; Table 4).
At 3 months, the correlation coefficient between Hb level
and PERFORMoverall score was similar than at baseline visit
(r=−0.249, p<0.0001). A significant negative correlation was
also observed between 3-month changes in Hb level and
3-month changes in PERFORM score (r=−0.255, p<0.0001).
Fatigue in subgroups with and without improvement in Hb
Table 5 shows 3-month changes in fatigue scores in patients
with and without improvement in Hb level. At baseline, no
significant differences were observed between these two groups.
During the follow-up, mean changes in fatigue scores
were significantly different for the three questionnaires,
resulting in effect sizes ranging from 0.07 to 0.20 (absolute
values) in improved patients, and from 0.12 to 0.32 in non-
improved patients (Table 5).
Factors associated to fatigue
At baseline visit, factors associated to fatigue as measured
by overall PERFORM score were: Hb level (r=−0.215,
p<0.0001), low Karnofsky score (r=−0.275, p<0.0001), high
ferritin levels (r=0.338, p=0.040), need for caregiver (differ-
ence in mean versus patients who do not need care, +8.7,
p<0.0001), treatment with palliative intention (+5.2 versus
treatment with curative intention, p=0.001), and metastatic
tumor (+4.3 versus local tumor, p=0.018). No relationship
was found with age, gender, educational level, serum iron,
transferrin saturation, time since diagnosis, tumor location or
active cancer treatment (data not shown).
At 3 months, factors associated to fatigue were: longer
time since diagnosis, lower Karnofsky index, lower Hb at
baseline and at 3 months, lower change in Hb during the
follow-up, lower serum iron at baseline, lung cancer type,
metastatic tumor, active cancer treatment, chemotherapy
administration, palliative cancer treatment intention, heart
and/or respiratory failure, administration of ESA, and trans-
fusion use (Table 6).
After multivariate adjustment, the independent factors that
remained associated to fatigue (global PERFORM score) at
3 months were: a low Hb level (coefficient β +1.43 (+0.60
to +2.26) for each −1 g/dL, p=0.001), a low Karnofsky index
Table 2 Hematology and serum
biochemistry parameters in the




EPO epoetin, LDH lactate-
dehydrogenase
aThere were missing values in
the data set
Baseline visit 3-month visit P value
Valid Na Mean (SD) Valid Na Mean (SD)
Hemoglobin (g/dL) 667 10.1 (0.8) 527 11.2 (1.5) <0.001
Hematocrit (%) 650 30.5 (2.7) 519 33.6 (4.5) <0.001
Leucocyte (103/mm3) 654 6.3 (3.6) 522 6.3 (3.4) 0.666
Lymphocytes (103/mm3) 386 1.4 (0.7) 280 1.4 (0.7) 0.706
Neutrophils (103/mm3) 389 3.9 (2.5) 278 3.8 (2.1) 0.716
Platelets (103/mm3) 637 282.2 (133.2) 519 247.7 (111) <0.001
Sodium (mEq/L) 474 139.2 (3.2) 414 139.5 (3.4) 0.133
Potassium (mEq/L) 466 4.3 (0.5) 403 4.3 (0.5) 0.326
AST (U/L) 395 25.9 (23.8) 348 32.5 (31.8) 0.002
ALT (U/L) 408 28.2 (22.9) 356 29.5 (22.7) 0.243
Glucose (mmol/L) 486 5.9 (1.9) 421 5.7 (1.7) 0.007
Albumin (g/dL) 254 3.8 (0.6) 250 3.9 (0.6) <0.001
Bilirubin (mg/dL) 410 0.5 (0.4) 357 0.6 (0.3) 0.164
Creatinine (mg/dL) 550 0.9 (0.4) 470 0.9 (0.4) 0.380
LDH (U/L) 300 424.8 (242.9) 276 404.3 (222) 0.329
Serum iron (μg/dL) 78 51.2 (33.5) 71 58.9 (28.5) 0.026
Ferritin (ng/dL) 48 300.3 (316.4) 49 275.8 (291.2) 0.652
Transferrin (%) 37 18 (7.5) 41 17.8 (8.8) 0.837
Vitamin B12 (pg/mL) 40 582.9 (501.4) 45 592.1 (400.1) 0.400
Folic acid (ng/mL) 39 9.2 (6) 34 10.3 (6.2) 0.518
Endogenous EPO (IU/L) 4 56.7 (39.9) 7 50.8 (30.5) 0.777
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(coefficient β +0.19 (+0.08 to +0.29) for each +1 %,
p<0.0001), active chemotherapy (coefficient β 5.07 (+1.81
to +8.32), p=0.002), cancer treatment with palliative intention
(coefficient β +2.97 (+0.33 to +5.61), p=0.028), and transfu-
sion need in the last 3 months (coefficient β +4.66 (+0.34 to +
8.98), p=0.035).
Discussion
The PERFORM questionnaire is a brief, recently validated
scale, specifically developed in the Spanish cultural envi-
ronment, for the assessment of perceptions and beliefs about
cancer-related fatigue, which has demonstrated excellent
psychometric properties [30]. The present study constitutes
the first use of this 12-item tool in the routine management
of Spanish cancer patients.
At baseline, we administered the PERFORM questionnaire
to a cohort characterized by low Hb levels, with the aim to
describe the relationship between anemia and perception of
fatigue by patients. The significant correlation found between
Table 3 Description of anemia degree, treatments for anemia, and patient-perception of fatigue in the study population at baseline and 3-month visits
Valid Na Baseline visit Valid Na 3-month visit P value
Anemia degree (g/dL) 667 527 <0.001
No anemia (>11 g/dL) 0 299 (56.7)
Mild anemia (>10 to ≤11 g/dL) 434 (65.1) 128 (24.3)
Moderate anemia (≥8 to ≤10 g/dL) 222 (33.3) 87 (16.5)
Severe anemia (<8 g/dL) 11 (1.6) 13 (2.5)
Type of treatment for anemia, N (%) 667 541 <0.001
None 384 (57.6) 239 (44.2)
Only transfusions 32 (4.8) 36 (6.6)
Only supplements 69 (10.3) 67 (12.4)
Only ESA 90 (13.5) 80 (14.8)
Transfusions+supplements 12 (1.8) 11 (2)
Transfusion+ESA 20 (3) 29 (5.4)
ESA+supplements 47 (7) 56 (10.3)
Transfusion+ESA+supplements 13 (1.9) 23 (4.3)
PERFORM questionnaire, mean (SD)
Global score 542 33.4 (13.2) 427 31.9 (13.3) 0.051
Activities of daily living 618 11.1 (4.3) 483 10.7 (4.4) 0.140
Beliefs and attitudes 584 11.4 (4.7) 461 10.8 (4.7) 0.036
Physical limitations 633 11.0 (5.0) 500 10.5 (5.0) 0.106
VAS fatigue (mm), mean (SD) 652 45.5 (27.6) 510 46.4 (28.8) 0.597
LASA (mm), mean (SD)
Energy 656 52.3 (23.7) 512 56.0 (24.5) 0.006
Activities of daily living 652 53.6 (27.2) 512 58.1 (26.6) 0.003
Overall quality of life 656 56.1 (23.7) 514 59.7 (24.5) 0.004
Each patient could have more than one response; supplements include: iron, B12 vitamin, folic acid
ESA erythropoiesis-stimulating agents, LASA Linear Analogue Self-Assessment, SD standard deviation, VAS Visual Analogue Scale
a There were missing values in the data set
Table 4 Correlation between hemoglobin level and patient-perception of








Global score 542 −0.215 <0.001
Activities of daily living 618 −0.187 <0.001
Beliefs and attitudes 584 −0.221 <0.001
Physical limitations 633 −0.164 <0.001
VAS fatigue 652 −0.134 <0.001
LASA
Energy 656 0.108 0.005
Activities of daily living 652 0.099 0.010
Overall quality of life 656 0.103 0.007
LASA Linear Analogue Self-Assessment, VAS Visual Analogue Scale
a There were missing values in the data set
b Rho Spearman
































































































































































































































































































































































































































































































































































































































































































































































































































































Support Care Cancer (2013) 21:3039–3049 3045
the Hb level and the three fatigue measures (the PERFORM
questionnaire and the two control measures LASA and VAS),
ranging between 0.10 and 0.22, is in line with what has been
published so far in the literature [12]. During the follow-up,
approximately 50% of patients had their anemia corrected, and
the PERFORM questionnaire was able to capture an improve-
ment in fatigue perception, whereas the LASA scale did not
show a significant change. In patients without Hb improve-
ment, an overall worsening of fatigue and QoL was observed,
suggesting that patient’s overall status had deteriorated due to
cancer progression. In the multivariate analysis, a decrease in
Hb levels as little as 1 g/dL was independently associated to a
worsening of fatigue perception, after controlling by demo-
graphic and clinical characteristics, cancer and anemia treat-
ments, and other biochemistry values. Thus, our results suggest
that 1 g/dL is a noteworthy change for the patient’s point of
view, at least in anemic patients. In a study with patients in
palliative care, differences in fatigue were observed only be-
tween subgroups defined by a cutoff level of 10 g/dL, but not
when the cutoff level was set to 12 g/dL [33]. We noticed a
similar degree of correlation between fatigue and absolute Hb
levels at baseline and at 3 months, after anemia correction,
which suggests that further benefits can be observed in patient-
reported fatigue at levels above 11 g/dl. A previous study of
anemia correction with epoetin alfa reported that the greatest
QoL increase was recorded when patients approached an Hb
level of 12 g/dL, independent of the baseline Hb level [13].
Regarding themanagement of anemia in the study sample, it
is similar than that described in previous studies [15], although
we found a slightly higher use of iron supplementation than in
Table 6 Association between
clinical and sociodemographic
characteristics of cancer patients
and perception of fatigue at
3-month visit (PERFORM
questionnaire, overall score)
No significant association was
observed between overall PER-
FORM score and the following
variables: age, gender, ferritin
levels, transferrin saturation, ra-
diotherapy, hormone therapy,
monoclonal antibodies, interfer-
on, symptomatic treatment, sup-
plements, chronic kidney dis-
ease, anxiety and/or depression,
dehydration and/or malnutrition
and/or diarrhea, infection, liver
disease, sleep disorders
CI confidence interval, ESA
erythropoiesis-stimulating agent
PERFORM score at 3 months
Continuous variables Coefficient of correlation P value
Time since diagnosis 0.099 0.042
Karnofsky index −0.199 <0.0001
Hemoglobin at baseline −0.115 0.017
Hemoglobin at 3 months −0.249 <0.0001
Change in hemoglobin −0.196 <0.0001
Serum iron at baseline −0.307 0.048
Categorical variables Difference in mean PERFORM score (95 % CI) P value
Cancer type 0.012
Lung +4.5 (+7.9 to +1.0)
Other Reference
Spread of cancer, N (%) 0.002
Local Reference
Locoregional +0.9 (−2.6 to +4.3)
Metastatic +5.4 (+2.2 to +8.5)
Cancer treatment 0.002
Without treatment Reference
In treatment +7.0 (+3.8 to +10.2)
Type of cancer treatment <0.0001
Chemotherapy +5.9 (+3.0 to +8.8)
Without chemotherapy Reference
Cancer treatment intention <0.0001
Palliative +6.3 (+3.9 to +8.7)
Adjuvant or curative Reference
Comorbidities 0.030
Heart and/or respiratory failure +5.3 (+0.6 to +10.0)
Without heart and/or respiratory failure Reference
Type of treatment for anemia 0.006
Transfusions +6.3 (+2.0 to +10.7)
Without transfusions Reference
Type of treatment for anemia 0.001
ESA +5.0 (+2.1 to +7.9)
Without ESA Reference
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the ECAS. Besides Hb level, other factors associated to fatigue
in our cohort were the presence of advanced disease (as indi-
cated by the significance of the variable “palliative cancer
treatment intention”), chemotherapy administration, and a low
Karnofsky index. The relationship found with transfusion need
could be explained by the fact that transfusions have only
transient effects, and have a limited capacity to ameliorate the
symptoms of anemia [34, 35].
We found no significant relationship between fatigue and
age, as previously described [36]. Gerber et al. [14], in a
cohort of breast cancer patients, found that the biological
characteristics associated with fatigue were high body mass
index and white blood cell counts. Other studies in breast
and liver cancer [37, 38] and in patients with palliative care
[33] found that fatigue was associated to psychological
factors such as distress, depression, or anxiety (less preva-
lent in our sample). Through the results of the present and
other recent studies, it is becoming evident that cancer-
related fatigue has several causal mechanisms [14]. For this
reason, an individualised approach to its therapeutic man-
agement is needed [39–46].
The present study supports the potential usefulness of
the brief PERFORM questionnaire for quickly assessing
patient perception of fatigue in the clinical practice. A
systematic review conducted in 2009 identified an ex-
tremely high number (up to 40) of validated instruments
for measuring fatigue in cancer patients [47]. Only few of
them were optimally tested for validity and reliability
[48], and most tools were relatively insensitive to differ-
ences in fatigue to cancer stage. In addition, most instru-
ments were too long to be administered in patients with
advanced cancer. In the present study, the PERFORM ques-
tionnaire, which is almost as short as the nine-item Brief
Fatigue Inventory, has demonstrated good sensitivity to
change, and has the advantage over other tools that includes
beliefs and attitudes of patients about fatigue. It is possible that
this newly added dimension explains our findings about fac-
tors predicting fatigue not found in any previous study (i.e.,
transfusion need).
The main limitation of the study is the observational
design, which does not allow the establishment of causal
relationships. Treatment bias does not allow comparing out-
comes in Hb or fatigue between subgroups defined by
therapeutic management of anemia. Indirect associations
between unmeasured variables and some of the described
factors predicting fatigue might account for some of our
findings, and thus results must be interpreted with caution.
Conclusions
Minimal increases or decreases in Hb of ≥1 g/dL were asso-
ciated with meaningful changes in patient-perceived fatigue as
measured with the brief, 12-item PERFORM question-
naire. In addition to anemia severity, other factors such as
active chemotherapy and advanced disease contribute to
perceptions of fatigue by cancer patients. These results
represent new evidence of the potential usefulness of PER-
FORM questionnaire for monitoring symptoms of fatigue
in cancer patients.
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